SCHEMBL5367979

SCHEMBL5367979

O=C(O)c1cccc(/C=N\NC(=S)Nc2ccccc2-c2ccccc2)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 5/20 0.56
PKM P14618 1/20 0.55
HNF4A P41235 1/20 0.47
KDM4E B2RXH2 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
GAA P10253 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MAPT P10636 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
LMNA P02545 1/20 0.45
NR2F2 P24468 1/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
TNF P01375 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367988 1.00 STS (0.56) STSPKMHNF4AKDM4EL3MBTL1
SCHEMBL5364181 0.79 MAPT (0.54) STSPKMKDM4EL3MBTL1GAA
SCHEMBL5364183 0.79 MAPT (0.54) STSPKMKDM4EL3MBTL1GAA
SCHEMBL27990133 0.76 L3MBTL1 (0.76) STSPKMKDM4EL3MBTL1GAA
SCHEMBL18196458 0.72 MEN1 (0.74) KDM4EL3MBTL1MEN1KMT2ANPC1
SCHEMBL5372825 0.70 MAPT (0.54) PKMKDM4EL3MBTL1GAAMEN1
SCHEMBL5372829 0.70 MAPT (0.54) PKMKDM4EL3MBTL1GAAMEN1
SCHEMBL5180635 0.70 PKM (0.68) STSPKMKDM4EL3MBTL1GAA
SCHEMBL5180641 0.70 PKM (0.68) STSPKMKDM4EL3MBTL1GAA
SCHEMBL8209116 0.70 HNF4A (0.67) HNF4AKDM4EFABP3FABP4FABP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP claimed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP claimed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK STS 1749/4885PKM 3743/4885HNF4A 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.